Immunyx Pharma acquired by Gilead Sciences for $100M (2018) | StartupHub.ai | StartupHub.ai

StartupHub.ai: AI Ecosystem Hub

Discover

Home
Search
Jobs
News
Rankings
Deals
Watchlist
Lists

Intelligence

Market Analysis
Comparison
Claude's Corner
Claude's Trades
Agentic Arbitrage
Today in AI Podcast

Tools

Founder Game

Company

Pricing
Solutions
Advertise
Publish Content
Affiliate Program
About
Terms
Privacy

Account

Home

Immunyx Pharma Acquisition 2018

Loading exit event...

The leading intelligence layer for the startup ecosystem. Over 20,000 AI startups, curated, scored, and agent-ready, backed by 65M+ company profiles and 5B+ AI-enriched data points you can query in real time through our RAG API.

GDPR CCPA SSL Privacy MCP Ready RFC 9727 llms.txt Agent Skills

AI Daily Digest

Top AI & startup news each morning

+42k readers

Discover

Universal Search
Startups
Investors
People
Funding Rounds
Rankings
Trending
Lists
Companies by Tech

Free Tools

Email Validator
Email Finder
AI Agent Readiness
Market Map Maker
PDF Maker
YouTube Transcript
Humanize AI Text
RSS Feed Generator
RSS for Zapier / Make / n8n
Watchlist
MCP Servers

For Founders & Devs

List via AI
NEW
Submit a Profile
Guides: Get Listed
NEW
Submit Article
Sell Your Startup
Pricing
Advertise
Embed Our Badge
Affiliate Program
NEW
API Docs
New Startups API
NEW
Agent Readiness Docs

Integrations

Setup wizard
NEW
All integrations
Clay
Zapier
n8n
Make
MCP Server

Company

AI News
Today in AI Podcast
NEW
About
Contact
Write for Us
Publish a Post · Newswire
Research
Terms of Service
Privacy Policy
Affiliate Disclosure

Compare

Crunchbase
PitchBook
CB Insights
Harmonic
Hunter
Apollo
Skrapp
Snov.io
Macabacus

© 2026 StartupHub.ai. All rights reserved. Terms · Privacy

security.txt RSS Sitemap

Gilead Sciences → Immunyx Pharma

Gilead Sciences → Immunyx Pharma

Gilead Sciences → Immunyx Pharma header image

Gilead Sciences → Immunyx Pharma

Gilead Sciences → Immunyx Pharma

2017New York, United States

Profile section

About

TypeAcquisition

AcquirerGilead Sciences

Consideration$100.0M

AnnouncedSeptember 2018

Deal details

Consideration$100M

TypeAcquisition

AcquirerGilead Sciences

AnnouncedSep 17, 2018

Exit score

58/100

Solid

A solid exit with healthy economics.

Deal size vs peers
Below the typical Acquisition.
Liquidity type
Strategic acquisition, a clean liquidity event.

Heuristic read of deal size vs peers, return multiple, acquirer premium, and liquidity type. Not investment advice.

vs. Acquisition deals (1,000)

Deal size distribution25th pct

smaller Acquisition dealslarger

Immunyx Pharma acquired by Gilead Sciences for $100M (2018) | StartupHub.ai | StartupHub.ai